{
}
Trading activity is subdued ahead of the Christmas holidays, with many market participants taking a break. The Dow is up 13% this year, while the Nasdaq 100 has nearly doubled that gain, despite Walmart shares dropping over 3% due to a lawsuit. Oil prices fell as the dollar strengthened, impacting crude costs.
Eight S&P 500 stocks that surged 30% or more in 2024 are projected to gain at least another 20% in 2025, according to analysts. Nvidia, which rose 182% this year, is expected to increase by 23.7%, while Eli Lilly, up 36.6%, is forecasted to gain 23.6%. Other notable performers include Leidos Holdings, Dell Technologies, and Delta Air Lines, all anticipated to continue their upward momentum.
U.S. stocks showed mixed results as the Dow dipped 0.2%, while the S&P 500 and Nasdaq rose 0.3% and 0.7%, respectively, amid hopes for a Santa Claus rally. Eli Lilly's shares climbed after the approval of its weight-loss drug for sleep apnea, while Treasury yields hit a new high at 4.58%. Economic data revealed a drop in consumer confidence and disappointing new home sales, with the stock market closing early on Tuesday and remaining shut on Wednesday.
UBS analyst Trung Huynh reports that Novo Nordisk's CagriSema Phase 3 obesity data fell short of expectations, achieving a 20.4% average weight loss compared to the anticipated 25%. This outcome is seen as favorable for Eli Lilly and Amgen, reinforcing tirzepatide's leading position in the market. The analysis suggests that CagriSema's efficacy aligns more closely with MariTide, which may present gastrointestinal issues and a less appealing monthly titration regimen.
UBS analyst Trung Huynh reports that Novo Nordisk's CagriSema Phase 3 obesity data fell short of expectations, achieving a 20.4% average weight loss compared to the anticipated 25%. This outcome is seen as favorable for Eli Lilly and Amgen, reinforcing tirzepatide's leading position and suggesting CagriSema's efficacy aligns more closely with MariTide, which may have gastrointestinal side effects.
U.S. stocks rebounded on Friday, with the S&P 500 and Dow Jones Industrial Average both rising 1.4%, as better-than-expected inflation data eased concerns over interest rate cuts. Despite this, the market remains cautious amid political uncertainty and potential global trade challenges. Notable declines included U.S. Steel, down 4.9%, and Novo Nordisk, which fell 17% after disappointing news on a weight-loss treatment.
The Dow Jones Industrial Average surged nearly 400 points, reversing a 10-day losing streak, as investors reacted positively to a lower-than-expected inflation report, despite looming government shutdown concerns. Nvidia's stock attempted a recovery, while shares of Trump Media and Technology fell sharply after the president-elect moved shares to a revocable trust. FedEx initially soared over 20% on earnings but later declined, while Carnival's stock rose 3% following better-than-expected quarterly results.
Novo Nordisk experienced a significant drop in stock value, plummeting over 22% after clinical trial results for its weight-loss drug Cagrisema fell short of expectations, with participants losing an average of 22.7% of their weight compared to the anticipated 25%. Despite a 21% rise in net profit in the previous quarter and strong sales for its other products, the company faces increasing competition and production capacity challenges. The World Obesity Federation forecasts a growing market for weight-loss treatments, highlighting the potential for future growth amid rising obesity rates globally.
Novo Nordisk's shares plummeted over 21% following disappointing results from the Phase 3 trial of its obesity drug CagriSema, which achieved a 22.7% average weight reduction, falling short of the expected 25%. Analysts have reacted with downgrades, citing safety concerns and underperformance compared to competitors. Despite achieving primary study objectives, the market's response reflects significant investor disappointment.
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1,100 Danish crowns. Analyst Jo Walton highlighted disappointing results for the weight loss drug Cagrisema, which showed a 20.4% reduction, falling short of the expected 25%. Future focus may shift towards availability, tolerability, and convenience of oral administration rather than efficacy.
Eli Lilly and Company
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
trading activity slows ahead of christmas as markets prepare for new year
Euro
United States Dollar
Japanese Yen
Swiss Franc
Walmart Inc.
Relief Therapeutics Holding SA
Micron Technology, Inc.
Eli Lilly and Company
Novartis AG
Tether USDt CNY
WISeKey Internat.Holding Ltd. N
USD/AMD
Broadcom Inc.
Qualcomm Inc
RumbleOn, Inc.
Apple Inc.
Arm Holdings plc
Hoffmann-La Roche AG
Nestlé S.A.
Eli Lilly
Show more
07:03 27.12.2024
top s p 500 stocks predicted to soar in 2025
General Electric Co
Trimble Inc.
Leidos Holdings, Inc.
Dell Technologies Inc.
Constellation Energy Corp
Eli Lilly and Company
Delta Air Lines, Inc.
NVIDIA Corporation
USA
Show more
14:00 24.12.2024
mixed market performance as chip stocks boost nasdaq and eli lilly rises
United States Dollar
Apple Inc.
Amazon.com, Inc.
Eli Lilly and Company
Microsoft Corp
MicroStrategy Inc
Tesla, Inc.
NVIDIA Corporation
Alphabet Inc.
USA
Eli Lilly
Joe Biden
Show more
15:02 23.12.2024
Novo obesity data boosts outlook for Eli Lilly and Amgen stocks
13:30 21.12.2024
Eli Lilly and Amgen benefit from Novo Nordisk's disappointing obesity data
13:30 21.12.2024
us stocks rebound as inflation data eases market fears
United States Dollar
NVIDIA Corporation
Shoe Carnival, Inc.
Norwegian Cruise Line Holdings Ltd.
NIKE, Inc.
U. S. Steel Canada Inc. Retirement Plan for CAW Local 523 Employees of the Former Stelpipe Ltd.
Novo Nordisk A/S
Eli Lilly and Company
USA
Donald Trump
David Burritt
Carl B. Weinberg
Elliott Hill
Josh Weinstein
Jerome Powell
Show more
01:00 21.12.2024
dow jones surges as inflation eases amid looming government shutdown
United States Dollar
Microsoft Corporation
Apple Inc.
Shoe Carnival, Inc.
NIKE, Inc.
Novo Nordisk A/S
Metagenomi, Inc.
Amazon.com, Inc.
Eli Lilly and Company
Tesla, Inc.
NVIDIA Corporation
FedEx Corp
Berkshire Hathaway Inc.
Alphabet Inc.
OCCIDENTAL PETROLEUM
USA
Donald Trump
Warren Buffett
Show more
16:58 20.12.2024
novo nordisk shares plunge after disappointing weight loss drug trial results
United States Dollar
Novo Nordisk A/S
Eli Lilly and Company
DNK
Martin Holst Lange
Mads Krogsgaard Thomsen
Show more
15:46 20.12.2024
novo nordisk faces stock plunge after disappointing results for obesity drug
Danish Krone
Catalent, Inc.
Novo Nordisk A/S
Eli Lilly and Company
DNK
Florent Cespedes
Emmanuel Papadakis
Jo Walton
Peter Welford
Show more
15:35 20.12.2024
ubs maintains neutral rating on novo nordisk amid disappointing weight loss data
15:17 20.12.2024
Trending
Subcategory
Corporate News
Startups & Entrepreneurship
Industry Trends
Global Trade Developments
Stock Market Updates
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Supply Chain Management
Private Equity Deals
Government Economic Policies
Cryptocurrency Trends
Retail and Consumer Goods
Workplace Trends
Venture Capital Investments
Fintech Startups
CEO Changes
Central Bank Actions
Central Banks and Digital Currencies
Energy Sector Developments
Crypto Policies and Governance
Countries:
Companies:
Apple Inc.
Foxconn Technology Co., Ltd.
NVIDIA Corporation
Nasdaq 100 Jun 25
Tesla, Inc.
Tencent Holdings Ltd
Google Inc.
NIO Inc.
Nikkei 225
Nintendo Co., Ltd.
Grab2Go AS
OLA ELECTRIC MOBILITY LTD
Boeing Co
Airbus SE
Amazon.com, Inc.
Oracle AI USD
AppLovin Corp.
Tesmec S.p.A.
DeepSeek R1 USD
LG Electronics Inc.
Currencies:
United States Dollar
Euro
Indian Rupee
Chinese Yuan
Japanese Yen
United Arab Emirates Dirham
New Taiwan Dollar
Indonesian Rupiah
Saudi Riyal
Offshore Chinese Yuan
Egyptian Pound
Hong Kong Dollar
Malaysian Ringgit
Filipino Peso
West African CFA Franc
South Korean Won
Thai Baht
Mexican Peso
Croatian Kuna
Bahraini Dinar
People: